These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 30795693

  • 1. Mepolizumab in adolescents with severe eosinophilic asthma not eligible for omalizumab: one center's early clinical experience.
    Weir E, Paton J.
    J Asthma; 2020 May; 57(5):521-524. PubMed ID: 30795693
    [No Abstract] [Full Text] [Related]

  • 2. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
    Carpagnano GE, Pelaia C, D'Amato M, Crimi N, Scichilone N, Scioscia G, Resta O, Calabrese C, Pelaia G, Quarato CMI, Foschino Barbaro MP.
    Ther Adv Respir Dis; 2020 May; 14():1753466620929231. PubMed ID: 32482128
    [No Abstract] [Full Text] [Related]

  • 3. Mepolizumab in children and adolescents with severe eosinophilic asthma not eligible for omalizumab: a single Center experience.
    Lim YT, Williams TC, Langley RJ, Weir E.
    J Asthma; 2024 Aug; 61(8):793-800. PubMed ID: 38240489
    [Abstract] [Full Text] [Related]

  • 4. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
    Liu MC, Chipps B, Munoz X, Devouassoux G, Bergna M, Smith SG, Price RG, Galkin DV, Azmi J, Mouneimne D, Albers FC, Chapman KR.
    Respir Res; 2021 May 10; 22(1):144. PubMed ID: 33971856
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.
    Humbert M, Albers FC, Bratton DJ, Yancey SW, Liu MC, Hozawa S, Llanos JP, Kwon N.
    Respir Med; 2019 May 10; 154():69-75. PubMed ID: 31220806
    [Abstract] [Full Text] [Related]

  • 8. Update: Mepolizumab treatment in patients with severe eosinophilic asthma and prior omalizumab use.
    Albers FC, Hozawa S, Bratton DJ, Yancey SW, Prazma CM, Humbert M, Liu MC.
    Allergy; 2020 Apr 10; 75(4):942-946. PubMed ID: 31520471
    [No Abstract] [Full Text] [Related]

  • 9. Proportion of Severe Asthma Patients Eligible for Mepolizumab Therapy by Age and Age of Onset of Asthma.
    Comberiati P, McCormack K, Malka-Rais J, Spahn JD.
    J Allergy Clin Immunol Pract; 2019 Apr 10; 7(8):2689-2696.e2. PubMed ID: 31201938
    [Abstract] [Full Text] [Related]

  • 10. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment.
    Magnan A, Bourdin A, Prazma CM, Albers FC, Price RG, Yancey SW, Ortega H.
    Allergy; 2016 Sep 10; 71(9):1335-44. PubMed ID: 27087007
    [Abstract] [Full Text] [Related]

  • 11. Severe uncontrolled eosinophilic asthma, which responded to benralizumab after failure to respond to mepolizumab.
    Kurosawa M, Sutoh E.
    Ann Allergy Asthma Immunol; 2019 Apr 10; 122(4):431-433. PubMed ID: 30578859
    [No Abstract] [Full Text] [Related]

  • 12. Comparative effectiveness of mepolizumab and omalizumab in severe asthma: An indirect treatment comparison.
    Cockle SM, Stynes G, Gunsoy NB, Parks D, Alfonso-Cristancho R, Wex J, Bradford ES, Albers FC, Willson J.
    Respir Med; 2017 Feb 10; 123():140-148. PubMed ID: 28137490
    [Abstract] [Full Text] [Related]

  • 13. Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma.
    Carpagnano GE, Resta E, Povero M, Pelaia C, D'Amato M, Crimi N, Scichilone N, Scioscia G, Resta O, Calabrese C, Pelaia G, Barbaro MPF.
    Sci Rep; 2021 Mar 09; 11(1):5453. PubMed ID: 33750842
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response.
    Caminati M, Cegolon L, Vianello A, Chieco Bianchi F, Festi G, Marchi MR, Micheletto C, Mazza F, Tognella S, Senna G.
    Expert Rev Respir Med; 2019 Dec 09; 13(12):1205-1212. PubMed ID: 31592700
    [Abstract] [Full Text] [Related]

  • 17. Secondary loss of response to mepolizumab in severe eosinophilic asthma.
    Cormier M, Chaboillez S, Lemiere C.
    J Allergy Clin Immunol Pract; 2020 Feb 09; 8(2):736-738. PubMed ID: 31421278
    [No Abstract] [Full Text] [Related]

  • 18. Eosinophil-derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma.
    Howarth P, Quirce S, Papi A, Israel E, Mallett S, Bates S, Yancey S, Albers FC, Kwon N.
    Allergy; 2020 Aug 09; 75(8):2085-2088. PubMed ID: 32147844
    [No Abstract] [Full Text] [Related]

  • 19. A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting.
    Cameli P, Bergantini L, d'Alessandro M, Perruzza M, Cekorja B, Perillo F, Massa E, Ruzza A, Fossi A, Beltrami V, Sestini P, Bargagli E.
    Int Arch Allergy Immunol; 2020 Aug 09; 181(8):606-612. PubMed ID: 32516771
    [Abstract] [Full Text] [Related]

  • 20. Mepolizumab in the treatment of severe eosinophilic asthma: Results from a physician in the field.
    Strauss RA, Jawhari N.
    Ann Allergy Asthma Immunol; 2018 Jul 09; 121(1):121-123. PubMed ID: 29684570
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.